Health care M&A spending falls nearly 40% in 2012, lowest year on record since 2003; report

22 January 2013

In 2012, dealmakers committed $143.3 billion to finance the year’s activity in the health care merger, acquisition and takeover market. Although sizable, that total represents a 38% decline compared with the $231.0 billion spent in 2011. Last year ranks ninth out of the last 10 years in dollar volume, with only 2003’s $94.2 billion coming in lower, according to a new report from Irving Levin Associates.

In terms of the number of health care deals announced, however, the year was one of the busiest in the past decade, with 1,063 deals, up 5.9% compared with 2011’s 1,004. 2012 ranked second only to 2007, when 1,079 deals were announced. Both the technology and services sectors showed a modest gain in deal volume compared with 2011: the number of deals in the technology sector rose 2.0% and services increased by 8.9%.

Number of biotech deals up

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Biotechnology